Trial · NCT01617187
Results by group340
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 340
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in PANSS Total Score at Day 42 | Asenapine 2.5 mg BID | -17.4 | Standard Error 1.80 | score on a scale | |
| Change From Baseline in PANSS Total Score at Day 42 | Asenapine 5 mg BID | -21.7 | Standard Error 1.60 | score on a scale | |
| Change From Baseline in PANSS Total Score at Day 42 | Olanzapine 15 mg QD | -21.6 | Standard Error 2.32 | score on a scale | |
| Change From Baseline in PANSS Total Score at Day 42 | Placebo BID | -16.2 | Standard Error 1.71 | score on a scale | |
| Change From Baseline in CGI-S Score at Day 42 | Asenapine 2.5 mg BID | -0.9 | Standard Error 0.11 | score on a scale | |
| Change From Baseline in CGI-S Score at Day 42 | Asenapine 5 mg BID | -1.2 | Standard Error 0.10 | score on a scale | |
| Change From Baseline in CGI-S Score at Day 42 | Olanzapine 15 mg QD | -1.1 | Standard Error 0.14 | score on a scale | |
| Change From Baseline in CGI-S Score at Day 42 | Placebo BID | -1.0 | Standard Error 0.11 | score on a scale | |
| Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Baseline in PANSS Total Score) at Day 42 | Asenapine 2.5 mg BID | 14.6 | 0.11 | percentage of participants | |
| Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Baseline in PANSS Total Score) at Day 42 | Asenapine 5 mg BID | 25.2 | 0.10 | percentage of participants | |
| Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Baseline in PANSS Total Score) at Day 42 | Olanzapine 15 mg QD | 26.7 | 0.14 | percentage of participants | |
| Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Baseline in PANSS Total Score) at Day 42 | Placebo BID | 19.2 | 0.11 | percentage of participants | |
| Change From Baseline in Body Weight at Day 42 | Asenapine 2.5 mg BID | 1.3 | Standard Error 0.38 | kg | |
| Change From Baseline in Body Weight at Day 42 | Asenapine 5 mg BID | 1.3 | Standard Error 0.33 | kg | |
| Change From Baseline in Body Weight at Day 42 | Olanzapine 15 mg QD | 2.4 | Standard Error 0.47 | kg | |
| Change From Baseline in Body Weight at Day 42 | Placebo BID | 0.3 | Standard Error 0.35 | kg | |
| Change From Baseline in PANSS Total Score at Days 4, 7, 14, 21, 28 and 35 | Asenapine 2.5 mg BID | Day 4 | -4.0 | Standard Error 0.80 | score on a scale |
| Change From Baseline in PANSS Total Score at Days 4, 7, 14, 21, 28 and 35 | Asenapine 5 mg BID | Day 4 | -4.9 | Standard Error 0.76 | score on a scale |
| Change From Baseline in PANSS Total Score at Days 4, 7, 14, 21, 28 and 35 | Olanzapine 15 mg QD | Day 4 | -5.5 | Standard Error 1.15 | score on a scale |
| Change From Baseline in PANSS Total Score at Days 4, 7, 14, 21, 28 and 35 | Placebo BID | Day 4 | -4.8 | Standard Error 0.81 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01617187/results